Aflatoxin B1 modulates the insulin-like growth factor-2 dependent signaling axis. 2010

Tsuneyuki Ubagai, and Takane Kikuchi, and Toshio Fukusato, and Yasuo Ono
Department of Microbiology and Immunology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.

Although aflatoxin B(1) (AFB(1)) is known as a mycotoxin that induces hepatocellular carcinoma (HCC), its effects on HCC cells have not been sufficiently investigated. The HCC cell lines HepG2, Huh-6, Huh-7, and PLC were cultured (5 x 10(5)cells/ml) and various concentrations of AFB(1) were added. The expression levels of the alpha-fetoprotein (AFP), insulin-like growth factor-2 (IGF-2), and insulin-like growth factor-1 receptor (IGF-1R) genes in each sample were determined by real-time PCR, with the following results: (1) The level of AFP expression in HepG2 increased at 5-50 ng/ml of AFB(1) in a dose-dependent manner. The AFP expression level in Huh-6 increased at 0.01-5 ng/ml of AFB(1) in a dose-dependent manner and decreased to half controls level at 50 ng/ml of AFB(1). The AFP expression level in Huh-7 decreased to one-third the original level at 0.5-50 ng/ml of AFB(1). The AFP expression level in PLC decreased at 0-0.5 ng/ml of AFB(1) in a dose-dependent manner, and decreased to one-third at concentrations of AFB(1) between 0.5 and 50 ng/ml. (2) The IGF-2 and IGF-1R expression levels in Huh-6 increased more than 10-fold at 0.5-5 ng/ml of AFB(1), but decreased to half at 50 ng/ml of AFB(1). The IGF-2 and IGF-1R expression levels in other cell lines increased in a dose-dependent manner. AFB(1) induced translations of IGF-2 and IGF-1R and cell proliferation: When 50 ng/ml AFB(1) was administrated, cell numbers were 2.0-, 1.7-, and 1.5-fold higher than those of controls after 3 days of culture in HepG2, Huh-7, and PLC, respectively. Particularly, in Huh-6, it increased 2.5-fold higher than those of controls following 5 ng/ml AFB(1) administration. The ratio of fold-change phospho-IGF-1R in all cell lines that were treated with AFB(1), increased 1.1-1.5-fold. These results indicate that AFB(1) may enhance HCC cell proliferation through an IGF-2-dependent signal axis, although it remains to be investigated whether those effects are associated with human hepatocarcinogenesis resulting from AFB(1) exposure.

UI MeSH Term Description Entries
D007335 Insulin-Like Growth Factor II A well-characterized neutral peptide believed to be secreted by the LIVER and to circulate in the BLOOD. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on SOMATOTROPIN. It is believed to be a major fetal growth factor in contrast to INSULIN-LIKE GROWTH FACTOR I, which is a major growth factor in adults. IGF-II,Multiplication-Stimulating Activity,Somatomedin MSA,IGF-2,Insulin Like Growth Factor II,Insulin-Like Somatomedin Peptide II,Multiplication-Stimulating Factor,Somatomedin A,Factor, Multiplication-Stimulating,Insulin Like Somatomedin Peptide II,Multiplication Stimulating Activity,Multiplication Stimulating Factor
D008114 Liver Neoplasms, Experimental Experimentally induced tumors of the LIVER. Hepatoma, Experimental,Hepatoma, Morris,Hepatoma, Novikoff,Experimental Hepatoma,Experimental Hepatomas,Experimental Liver Neoplasms,Hepatomas, Experimental,Neoplasms, Experimental Liver,Experimental Liver Neoplasm,Liver Neoplasm, Experimental,Morris Hepatoma,Novikoff Hepatoma
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012334 RNA, Neoplasm RNA present in neoplastic tissue. Neoplasm RNA

Related Publications

Tsuneyuki Ubagai, and Takane Kikuchi, and Toshio Fukusato, and Yasuo Ono
September 2004, Cancer research,
Tsuneyuki Ubagai, and Takane Kikuchi, and Toshio Fukusato, and Yasuo Ono
July 1996, Hormone research,
Tsuneyuki Ubagai, and Takane Kikuchi, and Toshio Fukusato, and Yasuo Ono
May 1996, The Journal of cell biology,
Tsuneyuki Ubagai, and Takane Kikuchi, and Toshio Fukusato, and Yasuo Ono
January 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Tsuneyuki Ubagai, and Takane Kikuchi, and Toshio Fukusato, and Yasuo Ono
November 2003, Pediatric nephrology (Berlin, Germany),
Tsuneyuki Ubagai, and Takane Kikuchi, and Toshio Fukusato, and Yasuo Ono
October 2005, Mechanisms of ageing and development,
Tsuneyuki Ubagai, and Takane Kikuchi, and Toshio Fukusato, and Yasuo Ono
April 1998, Endocrine journal,
Tsuneyuki Ubagai, and Takane Kikuchi, and Toshio Fukusato, and Yasuo Ono
November 2001, The Journal of biological chemistry,
Tsuneyuki Ubagai, and Takane Kikuchi, and Toshio Fukusato, and Yasuo Ono
March 1996, Clinical science (London, England : 1979),
Tsuneyuki Ubagai, and Takane Kikuchi, and Toshio Fukusato, and Yasuo Ono
January 2016, Frontiers in oncology,
Copied contents to your clipboard!